The Massey Cancer Center is a matrix center located at Virginia Commonwealth University, whose mission is to provide comprehensive, cancer-focused basic, clinical, and population research, clinical services, outreach, and education to the State of Virginia and the nation. The major goals of the Cancer Center are 1) to facilitate high-quality basic, clinical, and population-based research focused on the cancer problem and 2) to promote interdisciplinary and transdisciplinary collaborations among the scientific programs and members of the Cancer Center and translate findings into more effective interventions for cancer prevention and treatment. During the last project period, NCI annual total cost funding for Cancer Center members increased from $15,777,576 to $18,011,992, and total peer-reviewed funding from $33,125,861 to $38,016,473. During this period we expanded translational and clinical research activities, increased high impact cancer-focused research, and increased transdisciplinary research. Major goals for the next grant period are to further enhance our translational-clinical research activities, increase the depth and scope of collaborative programmatic research, and intensify our research focus on the problems of health care disparities among racial, ethnic, and other underserved populations. Research activities of the Massey Cancer Center are earned out through five research programs: Cancer Cell Signaling, Cancer Molecular Genetics, Cancer Prevention and Control, Developmental Therapeutics, and Radiation Biology and Oncology. The translational programs include both basic research and either clinical/translational or applied population research so as to facilitate transdisciplinary collaboration and rapid implementation and dissemination of research findings. In order to provide support for the predominantly peer-reviewed research base of the scientific programs, the Cancer Center supports nine shared resources: Clinical Research;Biostatistics;Flow Cytometry;Biologic Macromolecule;Behavioral Measurement;Structural Biology;Transgenic/Knockout Mouse;Cancer Research Informatics and Services;and Tissue and Data Acquisition and Analysis. This application requests continuation of CCSG funding to provide partial support for these shared resources as well as for senior leadership, program leadership, administration, staff investigators, protocol-specific research, program planning and evaluation, protocol review and monitoring, data and safety monitoring, and developmental funds, which are necessary to facilitate and stimulate transdisciplinary cancer research and translation throughout the Cancer Center.

Public Health Relevance

The mission of MCC is to serve Virginia and the nation as an internationally recognized comprehensive research and treatment center dedicated to improving the quality of human life by eliminating suffering and death through development and delivery of more effective means for the detection, treatment, prevention, control and ultimate cure of cancer. The core of this mission is to facilitate interdisciplinary and transdisciplinary cancer research so as to harness the considerable intellectual talent and scientific resources of VCU and focus them on solving the nation's cancer problem.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016059-31S1
Application #
8546139
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1978-12-01
Project End
2017-04-30
Budget Start
2012-08-30
Budget End
2013-04-30
Support Year
31
Fiscal Year
2012
Total Cost
$76,207
Indirect Cost
$26,071
Name
Virginia Commonwealth University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Ma, Yibao; Min, Hae-Ki; Oh, Unsong et al. (2017) The lignan manassantin is a potent and specific inhibitor of mitochondrial complex I and bioenergetic activity in mammals. J Biol Chem 292:20989-20997
van der Weyden, Louise; Arends, Mark J; Campbell, Andrew D et al. (2017) Genome-wide in vivo screen identifies novel host regulators of metastatic colonization. Nature 541:233-236
Schurman, Lesley D; Smith, Terry L; Morales, Anthony J et al. (2017) Investigation of left and right lateral fluid percussion injury in C57BL6/J mice: In vivo functional consequences. Neurosci Lett 653:31-38
Newton, Jason; Hait, Nitai C; Maceyka, Michael et al. (2017) FTY720/fingolimod increases NPC1 and NPC2 expression and reduces cholesterol and sphingolipid accumulation in Niemann-Pick type C mutant fibroblasts. FASEB J 31:1719-1730
Manzanares, Miguel Á; Usui, Akihiro; Campbell, Deanna J et al. (2017) Transforming Growth Factors ? and ? Are Essential for Modeling Cholangiocarcinoma Desmoplasia and Progression in a Three-Dimensional Organotypic Culture Model. Am J Pathol 187:1068-1092
Arsenovic, Paul T; Mayer, Carl R; Conway, Daniel E (2017) SensorFRET: A Standardless Approach to Measuring Pixel-based Spectral Bleed-through and FRET Efficiency using Spectral Imaging. Sci Rep 7:15609
Lownik, Joseph C; Luker, Andrea J; Damle, Sheela R et al. (2017) ADAM10-Mediated ICOS Ligand Shedding on B Cells Is Necessary for Proper T Cell ICOS Regulation and T Follicular Helper Responses. J Immunol 199:2305-2315
Karki, Kishor; Saraiya, Siddharth; Hugo, Geoffrey D et al. (2017) Variabilities of Magnetic Resonance Imaging-, Computed Tomography-, and Positron Emission Tomography-Computed Tomography-Based Tumor and Lymph Node Delineations for Lung Cancer Radiation Therapy Planning. Int J Radiat Oncol Biol Phys 99:80-89
Meier, Jeremy A; Hyun, Moonjung; Cantwell, Marc et al. (2017) Stress-induced dynamic regulation of mitochondrial STAT3 and its association with cyclophilin D reduce mitochondrial ROS production. Sci Signal 10:
Benson, Zachary; Manjili, Saeed H; Habibi, Mehran et al. (2017) Conditioning neoadjuvant therapies for improved immunotherapy of cancer. Biochem Pharmacol 145:12-17

Showing the most recent 10 out of 499 publications